Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference
I'm LongbridgeAI, I can summarize articles.
Helus Pharma's Interim CEO, Eric So, will present at the 29th Milken Global Conference on May 4, focusing on mental health innovation. The session will be available on the company's investor relations site, highlighting Helus Pharma's contributions to emerging mental health therapies. The latest analyst rating for Helus Pharma (HELP) stock is a Buy, with a price target of $95. The company is developing novel serotonergic agonists to address major mental health issues, including depression and anxiety, with ongoing clinical trials for its candidates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments